Absci is trading at $10.02 (+5.58%), but the reason for the September 29 rise remains unclear.
- No new Absci announcement or clear catalyst for the move surfaced in available coverage. Its latest identified update, on September 24, detailed the planned Phase 2 STORYLINE trial of ABS-201 for endometriosis, anticipated to begin in mid-2027; this predates the session and does not establish the cause.
- Major indexes were mixed, so the supplied market context does not point to a broad-market explanation.